ARHGAP25 expression in colorectal cancer as a biomarker associated with favorable prognosis

Zhang,Yue; Lin,Yi; Zhu,Yingjie; Zhang,Xiaoyun; Tao,Li; Yang,Ming

doi:10.3892/mco.2022.2517

ARHGAP25 expression in colorectal cancer as a biomarker associated with favorable prognosis

Authors:
- Yue Zhang
- Yi Lin
- Yingjie Zhu
- Xiaoyun Zhang
- Li Tao
- Ming Yang
View Affiliations

Affiliations: Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China, Department of Pathology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China, Phase I Clinical Research Laboratory of Shanghai Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China
Published online on: February 16, 2022 https://doi.org/10.3892/mco.2022.2517
Article Number: 84
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although progress has been made in the early diagnosis of colorectal cancer (CRC) and in the systemic therapy of patients with CRC, the prognosis for advanced CRC remains poor. Our previous study demonstrated that ARHGAP25 overexpression significantly inhibits CRC cell growth, invasion and migration. However, it was not possible to evaluate and analyze the overall survival (OS) rate of patients with CRC. Thus, the discovery of relevant factors and their expression on the basis of existing research is necessary to predict the OS rate of patients with advanced CRC. Therefore, the aim of the present study was to define the value of Rho GTPase‑activating protein 25 (ARHGAP25) expression in predicting the OS rate in patients with CRC. The clinical data of 153 patients with CRC who underwent colorectal resection were retrospectively analyzed. In order to explore the expression of ARHGAP25, immunohistochemical analysis of the tumor tissues of these patients, was performed. Univariate Cox regression analysis was used to assess the prognostic value of ARHGAP25 expression for OS. Multivariate analysis was used to evaluate the effect of ARHGAP25 expression in the presence of other variables. Confounding factors and interaction were assessed by a stratified analysis using ARHGAP25 expression and other variables associated with survival. The univariate analysis revealed that, ARHGAP25 expression was associated with an improved OS in patients with CRC (P<0.05). The multivariate analysis revealed that ARHGAP25 expression was still correlated with an improved OS after adjusting for sex, age, invasion degree, lymph node metastasis, distant metastasis, TNM stage, tumor location, histological type, histological grade, tumor deposits, and postoperative treatment (P<0.05). The stratified analysis demonstrated that the predictive value of ARHGAP25 for the OS of patients with CRC was stronger in males, elderly patients (>70 years old), patients with T3 stage tumor, lymph node metastasis, TNM stage III, right hemicolon location and patients with a poorly differentiated tumor (P<0.05). Overall, our results demonstrated that ARHGAP25 may have an important potential value for improving the prognosis of patients with CRC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	Katoh M and Katoh M: Identification and characterization of ARHGAP24 and ARHGAP25 genes in silico. Int J Mol Med. 14:333–338. 2004.PubMed/NCBI
3	Lindner SE, Egelston CA, Huard SM, Lee PP and Wang LD: Arhgap25 deficiency leads to decreased numbers of peripheral blood B cells and defective germinal center reactions. Immunohorizons. 4:274–281. 2020.PubMed/NCBI View Article : Google Scholar
4	Csépányi-Kömi R, Sirokmány G, Geiszt M and Ligeti E: ARHGAP25, a novel Rac GTPase-activating protein, regulates phagocytosis in human neutrophilic granulocytes. Blood. 119:573–582. 2012.PubMed/NCBI View Article : Google Scholar
5	Csépányi-Kömi R, Wisniewski É, Bartos B, Lévai P, Németh T, Balázs B, Kurz AR, Bierschenk S, Sperandio M and Ligeti E: Rac GTPase activating protein ARHGAP25 regulates leukocyte transendothelial migration in mice. J Immunol. 197:2807–2815. 2016.PubMed/NCBI View Article : Google Scholar
6	Tao L, Zhu Y, Gu Y, Zheng J and Yang J: ARHGAP25: A negative regulator of colorectal cancer (CRC) metastasis via the Wnt/β-catenin pathway. Eur J Pharmacol. 858(172476)2019.PubMed/NCBI View Article : Google Scholar
7	Jensen EC: Quantitative analysis of histological staining and fluorescence using ImageJ. Anat Rec (Hoboken). 296:378–381. 2013.PubMed/NCBI View Article : Google Scholar
8	Varghese F, Bukhari AB, Malhotra R and De A: IHC profiler: An open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One. 9(e96801)2014.PubMed/NCBI View Article : Google Scholar
9	Choi J, Dekkers OM and le Cessie S: A comparison of different methods to handle missing data in the context of propensity score analysis. Eur J Epidemiol. 34:23–36. 2019.PubMed/NCBI View Article : Google Scholar
10	Pedersen AB, Mikkelsen EM, Cronin-Fenton D, Kristensen NR, Pham TM, Pedersen L and Petersen I: Missing data and multiple imputation in clinical epidemiological research. Clin Epidemiol. 9:157–165. 2017.PubMed/NCBI View Article : Google Scholar
11	White IR and Carlin JB: Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med. 29:2920–2931. 2010.PubMed/NCBI View Article : Google Scholar
12	Wong CK, Lam CL, Poon JT, McGhee SM, Law WL, Kwong DL, Tsang J and Chan P: Direct medical costs of care for Chinese patients with colorectal neoplasia: A health care service provider perspective. J Eval Clin Pract. 18:1203–1210. 2012.PubMed/NCBI View Article : Google Scholar
13	Vega FM and Ridley AJ: Rho GTPases in cancer cell biology. FEBS Lett. 582:2093–2101. 2008.PubMed/NCBI View Article : Google Scholar
14	Etienne-Manneville S and Hall A: Rho GTPases in cell biology. Nature. 420:629–635. 2002.PubMed/NCBI View Article : Google Scholar
15	Bernards A: GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta. 1603:47–82. 2003.PubMed/NCBI View Article : Google Scholar
16	Tcherkezian J and Lamarche-Vane N: Current knowledge of the large RhoGAP family of proteins. Biol Cell. 99:67–86. 2007.PubMed/NCBI View Article : Google Scholar
17	Thuault S, Comunale F, Hasna J, Fortier M, Planchon D, Elarouci N, De Reynies A, Bodin S, Blangy A and Gauthier-Rouvière C: The RhoE/ROCK/ARHGAP25 signaling pathway controls cell invasion by inhibition of Rac activity. Mol Biol Cell Cell. 27:2653–2661. 2016.PubMed/NCBI View Article : Google Scholar
18	Xu K, Liu B and Ma Y: The tumor suppressive roles of ARHGAP25 in lung cancer cells. Onco Targets Ther. 12:6699–6710. 2019.PubMed/NCBI View Article : Google Scholar
19	Derwinger K, Carlsson G and Gustavsson B: A study of lymph node ratio as a prognostic marker in colon cancer. Eur J Surg Oncol. 34:771–775. 2008.PubMed/NCBI View Article : Google Scholar
20	Mehrkhani F, Nasiri S, Donboli K, Meysamie A and Hedayat A: Prognostic factors in survival of colorectal cancer patients after surgery. Colorectal Dis. 11:157–161. 2009.PubMed/NCBI View Article : Google Scholar
21	Nitsche U, Friess H, Agha A, Angele M, Eckel R, Heitland W, Jauch KW, Krenz D, Nüssler NC, Rau HG, et al: Prognosis of mucinous and signet-ring cell colorectal cancer in a population-based cohort. J Cancer Res Clin Oncol. 142:2357–2366. 2016.PubMed/NCBI View Article : Google Scholar
22	Serra-Rexach JA, Jimenez AB, Garcia-Alhambra MA, Pla R, Vidán M, Rodriguez P, Ortiz J, García-Alfonso P and Martín M: Differences in the therapeutic approach to colorectal cancer in young and elderly patients. Oncologist. 17:1277–1285. 2012.PubMed/NCBI View Article : Google Scholar
23	Majek O, Gondos A, Jansen L, Emrich K, Holleczek B, Katalinic A, Nennecke A, Eberle A and Brenner H: GEKID Cancer Survival Working Group. Sex differences in colorectal cancer survival: Population-based analysis of 164,996 colorectal cancer patients in Germany. PLoS One. 8(e68077)2013.PubMed/NCBI View Article : Google Scholar
24	Compton C, Fenoglio-Preiser CM, Pettigrew N and Fielding LP: American joint committee on cancer prognostic factors consensus conference: Colorectal working group. Cancer. 88:1739–1757. 2000.PubMed/NCBI View Article : Google Scholar
25	Newland RC, Dent OF, Lyttle MN, Chapuis PH and Bokey EL: Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer. 73:2076–2082. 1994.PubMed/NCBI View Article : Google Scholar
26	Shepherd NA, Baxter KJ and Love SB: The prognostic importance of peritoneal involvement in colonic cancer: A prospective evaluation. Gastroenterology. 112:1096–1102. 1997.PubMed/NCBI View Article : Google Scholar
27	Park YJ, Park KJ, Park JG, Lee KU, Choe KJ and Kim JP: Prognostic factors in 2230 Korean colorectal cancer patients: Analysis of consecutively operated cases. World J Surg. 23:721–726. 1999.PubMed/NCBI View Article : Google Scholar
28	Vasile L, Olaru A, Munteanu M, Pleşea IE, Surlin V and Tudoraşcu C: Prognosis of colorectal cancer: Clinical, pathological and therapeutic correlation. Rom J Morphol Embryol. 53:383–391. 2012.PubMed/NCBI
29	Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, et al: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 25:1995–2001. 2014.PubMed/NCBI View Article : Google Scholar
30	Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ and Heinemann V: Prognostic and predictive relevance of primary tumor location in patients With RAS wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 3:194–201. 2017.PubMed/NCBI View Article : Google Scholar
31	Derwinger K, Kodeda K, Bexe-Lindskog E and Taflin H: Tumour differentiation grade is associated with TNM staging and the risk of node metastasis in colorectal cancer. Acta Oncol. 49:57–62. 2010.PubMed/NCBI View Article : Google Scholar
32	Kanazawa T, Watanabe T, Kazama S, Tada T, Koketsu S and Nagawa H: Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer. 102:225–229. 2002.PubMed/NCBI View Article : Google Scholar
33	Mirkin KA, Kulaylat AS, Hollenbeak CS and Messaris E: Prognostic significance of tumor deposits in stage III colon cancer. Ann Surg Oncol. 25:3179–3184. 2018.PubMed/NCBI View Article : Google Scholar
34	Nagayoshi K, Ueki T, Nishioka Y, Manabe T, Mizuuchi Y, Hirahashi M, Oda Y and Tanaka M: Tumor deposit is a poor prognostic indicator for patients who have stage II and III colorectal cancer with fewer than 4 lymph node metastases but not for those with 4 or more. Dis Colon Rectum. 57:467–474. 2014.PubMed/NCBI View Article : Google Scholar
35	Liu X, Xiu LJ, Jiao JP, Zhao J, Zhao Y, Lu Y, Shi J, Li YJ, Ye M, Gu YF, et al: Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: A retrospective clinical analysis. J Integr Med. 15:469–475. 2017.PubMed/NCBI View Article : Google Scholar
36	Yang X, Hao J, Zhu CH, Niu YY, Ding XL, Liu C and Wu XZ: Survival benefits of western and traditional Chinese medicine treatment for patients with pancreatic cancer. Medicine (Baltimore). 94(e1008)2015.PubMed/NCBI View Article : Google Scholar
37	Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A and Koutsilieris M: Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J Gastroenterol. 16:5965–5974. 2010.PubMed/NCBI View Article : Google Scholar
38	Diaconescu A, Alexandrescu S, Ionel Z, Zlate C, Grigorie R, Brasoveanu V, Hrehoret D, Ciurea S, Botea F, Tomescu D, et al: Resection of concomitant hepatic and extrahepatic metastases from colorectal cancer-a worthwhile operation? Chirurgia (Bucur). 112:673–682. 2017.PubMed/NCBI View Article : Google Scholar
39	Luo M, Chen SL, Chen J, Yan H, Qiu Z, Chen G, Lu L and Zhang F: Resection vs ablation for lesions characterized as resectable-ablative within the colorectal liver oligometastases criteria: A propensity score matching from retrospective study. PeerJ. 8(e8398)2020.PubMed/NCBI View Article : Google Scholar